Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Vilya Therapeutics is designing macrocycle drug candidates.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
References
Salveson, P. J. et al. Science https://doi.org/10.1126/science.adk1687 (2024).
Rettie, S. A. et al. Preprint at bioRxiv https://doi.org/10.1101/2024.11.18.622547 (2024).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenstein, M. Editor’s pick: Vilya Therapeutics. Nat Biotechnol 43, 1409–1410 (2025). https://doi.org/10.1038/s41587-025-02782-x
Published:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02782-x
